Policy & Regulation


  • Dr. Mehmet Oz arrives for his confirmation hearing with the Senate Finance Committee in the Dirksen Senate Office Building on March 14, 2025 in Washington, D.C.
    Image attribution tooltip
    Anna Moneymaker / Staff via Getty Images
    Image attribution tooltip

    Dr. Oz confirmed to lead CMS

    Dr. Mehmet Oz, a physician and TV personality, will lead the agency during a turbulent time for federal health programs as the HHS lays off thousands of staffers and Republicans float potential cuts to Medicaid.

    By Emily Olsen • April 4, 2025
  • HHS staff cuts
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip
    Opinion

    Industry leaders react to HHS being ‘reduced to a shell’

    What healthcare watchdogs have said about the far-reaching job cuts this week.

    By Meagan Parrish and Amy Baxter • April 3, 2025
  • rare disease ribbon Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Rare diseases

    As drug developers find promise in the rare diseases, deals and treatments are on the rise

    By PharmaVoice staff
  • megaphone quieted
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    With government health info in limbo, drugmakers lose credible sources

    The lack of clear communication from the government could spark wide-ranging issues in pharma — from sowing confusion about clinical trial design to further eroding public trust.

    By Alexandra Pecci • April 1, 2025
  • fda logo
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    FDA’s ‘mixed signals’ on diversity have entangled clinical trials. Here’s how pharma can push ahead.

    The agency is still unclear about where it will stand on clinical trial diversity, but companies are looking for answers and leaning toward good science.

    By March 28, 2025
  • The HHS in DC
    Image attribution tooltip
    Alex Wong / Staff via Getty Images
    Image attribution tooltip

    HHS announces sweeping reorganization, including cuts of 10K workers

    Along with shrinking the HHS’ workforce further, the reorganization announced Thursday will cut the department from 28 divisions to 15, and close five regional offices.

    By Rebecca Pifer • March 27, 2025
  • Robert F. Kennedy Jr. stands in front of croded congressional room
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Rx-to-OTC rule gets pushed back — again

    A delay of the prescription-to-OTC rule signals health agencies’ ongoing reluctance to implement new regulations.

    By March 26, 2025
  • Eli Lilly
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly, Novo expand DTC reach of obesity meds after compound win

    The FDA delisted semaglutide and tirzepatide from its shortage list, putting an end to copycat GLP-1s.

    By March 24, 2025
  • recession
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    How pharma could feel the pain of a recession

    Pharma has long been considered “recession proof,” but an economic downturn could still hurt the industry in numerous ways.

    By March 21, 2025
  • Florida Governor Ron DeSantis speaks at a podium.
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    Vaccine makers face mRNA backlash as states seek further restrictions

    A handful of states are targeting the technology at the same time the Trump administration is cutting research funding and revoking vaccine contracts.

    By March 19, 2025
  • china biotech
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The key factors shaping China’s biopharma boom

    Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles could stymie dealmaking.

    By Alexandra Pecci • March 19, 2025
  • Senator Elizabeth Warren speaks during a legislative hearing, holding her handout to the side. A sign in front of her reads "Ms. Warren."
    Image attribution tooltip
    Andrew Harnik / Staff via Getty Images
    Image attribution tooltip

    Lawmakers tease out pharma’s influence over RFK Jr. through probe into Mar-a-Lago meetings

    HHS head Robert F. Kennedy Jr. has long been an opponent of pharma influence in government. U.S. lawmakers are asking whether unofficial Mar-a-Lago meetings point to a change of heart.

    By March 13, 2025
  • The dome of the U.S. Capitol Building as seen at dawn.
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    IRA reforms, including a small molecule fix, could be on the table. Will Trump and the GOP make the leap?

    Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.

    By March 12, 2025
  • Colorful medical pills cover Benjamin Franklin's face on one hundred american dollar bill.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pricing transparency is in the spotlight — and that could be good news for drugmakers

    An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can efforts to bring transparency into that system now pan out?

    By March 11, 2025
  • Trade routes, tariffs
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    As tariffs loom over pharma manufacturing, a reshoring effort is underway — but not without challenges

    Experts say cost and other barriers present challenges to returning to U.S. shores.

    By Kelly Bilodeau • March 10, 2025
  • man in a navy suit with a red tie sits hands crossed at a desk with a microphone
    Image attribution tooltip
    Kayla Bartkowski via Getty Images
    Image attribution tooltip

    How will Makary lead FDA amid workforce cuts and RFK Jr.s’ influence?

    With President Trump’s nominee for FDA commissioner in Senate confirmation hearings, his approach to workforce cuts and other policies is under scrutiny.

    By March 7, 2025
  • A podium showing the logo for the Centers for Disease Control and Prevention is seen.
    Image attribution tooltip
    Kevin C. Cox via Getty Images
    Image attribution tooltip

    The top 3 impacts of Trump’s health data purge

    Interrupted access to health-related data has already led to worse outcomes and could undermine faith in the U.S. healthcare system, experts say.

    By Michael Brady • March 6, 2025
  • Capitol building, DC
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide

    Orphan drug development has long been incentivized by government policy. But as the financial math shifts, so do the risks of bringing rare disease drugs to market.

    By Feb. 25, 2025
  • RFK Jr. points a finger during a speech behind a podium
    Image attribution tooltip
    Chip Somodevilla via Getty Images
    Image attribution tooltip

    Kennedy’s MAHA agenda is tackling ‘conflicts of interest’ — and could take aim at FDA adcomms

    Health agency job cuts and a newly-established MAHA commission leave many unanswered questions about potential reforms and impact on drug approvals.

    By Feb. 24, 2025
  • A sign reading Food and Drug Administration is seen above a door to a government building.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    In FDA job cuts, experts see threat of far-reaching impact

    "Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency commissioner Robert Califf, of the layoffs.

    By Jonathan Gardner , Delilah Alvarado • Feb. 21, 2025
  • job cuts concept
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    A look at Trump’s healthcare cuts — so far

    How the federal workforce crackdown has impacted the agencies that oversee pharma and healthcare.

    By Feb. 21, 2025
  • Drug pricing
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    Medicare’s next list of drugs for price negotiation could get ‘very interesting’ — and have a bigger impact on pharma

    The Biden-era law is now in the hands of a new administration, and drugmakers are scanning the horizon for hints of a massive overhaul or incremental change.

    By Feb. 11, 2025
  • China trade tariffs
    Image attribution tooltip
    Anatolii Kovalov via Getty Images
    Image attribution tooltip

    Tariffs raise concern among generic drugmakers, and advocacy groups are seeking exemptions

    While the 10% tariff on Chinese goods won’t have too much impact on branded drugs, generics are struggling to pivot.

    By Kelly Bilodeau • Feb. 7, 2025
  • Robert Kennedy shakes hands with members of the senate finance committee
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    RFK Jr. will face these critical tests if confirmed as head of the HHS

    After a Senate committee advanced President Trump’s nominee to lead HHS, Robert F. Kennedy Jr. is poised to secure the top job at the nation’s healthcare agency.

    By Feb. 5, 2025
  • U.S. Agency for International Development supplies to be flown to Haiti.
    Image attribution tooltip
    David McNew/Getty Images via Getty Images
    Image attribution tooltip

    Looming USAID shutdown threatens global health presence and a legacy of medical foreign aid

    As President Trump and his cohorts plan to shut down the U.S. Agency for International Development, here’s what that could mean for global health and the drugmaking industry.

    By Feb. 4, 2025
  • Front sign of FDA building
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    What should pharma make of the FDA going dark on DEI?

    After a series of potent executive orders last week, the FDA removed draft guidance on diversity in clinical trials.

    By Feb. 4, 2025